Sarepta Therapeutics (SRPT) is back in focus after the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, a regulatory step that could influence how long these Duchenne muscular dystrophy therapies remain effective for patients.

Sarepta Therapeutics’ latest regulatory progress comes after a mixed period for investors, with the share price currently at $18.82, a strong 30 day share price return of 22.93% but longer term total shareholder returns over 3 and 5 years still significantly negative.

If this Duchenne muscular dystrophy update has you thinking about where biotech meets AI in healthcare, it could be a good moment to scan the market using our 40 healthcare AI stocks

After a sharp 30-day rebound, Sarepta Therapeutics still trades below both analyst targets and some fair value estimates. This leaves a key question: is the market rightly cautious about the company’s track record, or is it being too pessimistic about the upside?

Most Popular Narrative: 13.1% Undervalued

Compared with Sarepta Therapeutics’ last close at $18.82, the most followed narrative applies a fair value of $21.65 per share, using a 7.81% discount rate to frame long term cash flows.

Efforts to balance demand across affiliated treatment centers with additional capacity could improve the ability to treat more patients, advancing revenue growth as these centers become more effective and productive in patient throughput.

Want to see what sits behind that fair value for Sarepta Therapeutics? The narrative leans heavily on shifting margins, changing revenue trajectories and a richer earnings multiple. Curious which assumptions do the heavy lifting, and how they link to 2029 targets? The full story joins those moving parts into one valuation blueprint.

Result: Fair Value of $21.65 (UNDERVALUED)

However, the Sarepta Therapeutics story also carries execution and safety questions, with ELEVIDYS related liver risk and administrative bottlenecks at treatment centers both capable of challenging this upbeat valuation narrative.

Another View on Sarepta Therapeutics Valuation

That 13.1% gap to the $21.65 fair value is one story, but Sarepta Therapeutics looks very different when you look at the current P/E. At 30.5x, the stock trades well above the US Biotechs average of 17.4x and the 6.4x fair ratio that regression points to.

In practice, that means the market is already paying a premium multiple, even though the fair ratio suggests a level the valuation could move toward over time. Is this a sign that investors are pricing in more good news than the fundamentals currently support, or just reflecting confidence in Sarepta Therapeutics’ longer term pipeline?

Next Steps

If the mixed signals around Sarepta Therapeutics leave you undecided, this is the moment to move fast, review the data, and test your own thesis against the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Sarepta Therapeutics?

If Sarepta Therapeutics has sharpened your focus, do not stop here. Broaden your watchlist with stocks that match your risk comfort, return goals, and balance sheet preferences.

• Target potential value upside by scanning companies that combine quality fundamentals with attractive pricing using our 46 high quality undervalued stocks
• Secure more predictable cash flows by reviewing income focused opportunities screened with our 8 dividend fortresses
• Prioritize resilience by filtering for companies with sturdier finances through the solid balance sheet and fundamentals stocks screener (47 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.